PODD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Insulet Corp (PODD) does not present a strong buy opportunity for a beginner investor with a long-term horizon at this time. The stock is currently trading in a bearish technical trend, with no immediate positive signals from Intellectia Proprietary Trading Signals or recent news catalysts. Additionally, the cautious sentiment from Congress trading data and mixed analyst ratings further support a hold stance.
The stock is in a bearish trend with SMA_200 > SMA_20 > SMA_5. RSI is neutral at 41.845, and MACD is positive but contracting. The current price of $146.12 is below the pivot level of $151.119, with key support at $143.767 and resistance at $158.472.
Insider buying has increased significantly by 409.88% over the last month, indicating confidence from company insiders. Analysts highlight the company's elite growth profile and potential upside due to its international expansion and type 2 diabetes market penetration.
Congress members have sold $20M-$50M of the stock in the last 90 days, signaling caution. Analysts have lowered price targets due to competition, slower growth, and sector-wide challenges in MedTech. The stock faces risks from pricing pressures and manufacturing issues, which have impacted sentiment.
No financial data available for the latest quarter.
Analyst ratings are mixed, with several firms lowering price targets but maintaining Buy ratings. Price targets range from $165 to $280, with the median target reflecting limited upside from the current price. Analysts acknowledge the company's growth potential but highlight near-term challenges in the MedTech sector.
